Compare Quest Diagnostics Inc (DGX) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Krispy Kreme Inc — how do they compare? Quest Diagnostics Inc trades at $230.51 (market cap $25.48B), while Krispy Kreme Inc trades at $2.98 (market cap $521.37M). The key difference: Quest Diagnostics Inc is far larger — about 48.9× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Krispy Kreme Inc for 45 Days on average.
| DGX | DNUT | |
|---|---|---|
Market Cap | $25.48B | $521.37M |
Volume | 941,866 | 2,293,015 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $4.70 |
52-Week Low | $173.49 | $2.87 |
Typical Hold Time | 56 Days | 45 Days |
Enterprise Value | $31.23B | $1.76B |
Dividend Yield | 1.49% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Krispy Kreme (DNUT) trades at $2.92, down 3.31% today, amid bearish technical signals and negative profitability. The company reported a significant net loss of $515.77M in 2025 despite $1.52B revenue, with negative margins and declining cash flow from operations. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, creating investor uncertainty alongside seasonal product launches.
The outlook remains challenged by persistent losses and high debt levels, though analyst consensus leans bullish with 50% buy ratings. Key risks include legal overhangs, competitive pressure, and execution on profitability. Valuation metrics show mixed signals with low P/S but negative earnings, requiring careful monitoring of turnaround efforts and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
